Navigation Links
Neurim Pharmaceuticals Reports Long Term Efficacy and Safety for Circadin(R) for Insomnia in Elderly Patients
Date:6/11/2009

SEATTLE, June 11 /PRNewswire/ -- Neurim Pharmaceuticals (http://www.neurim.com) presented today the preliminary results of a large-scale Phase III study of Circadin(R) 2mg, prolonged release melatonin in insomnia, demonstrating long term efficacy and safety in elderly patients. The results were reported in the Late Breaking Abstracts session of SLEEP 2009, the 23rd Annual Meeting of the Associated Professional Sleep Societies, (APSS) held at Seattle, Washington. The SLEEP meeting attracts the largest audience of sleep specialists in world.

Circadin(R) http://www.Circadin.info) is a novel sleep medicine that has been approved by the European Commission pharmaceutical regulatory agency and the Israeli Ministry of Health for the short-term treatment of primary insomnia, characterized by poor quality of sleep in patients who are aged 55 and over. The approval is based on clinical studies showing positive effects on sleep quality, sleep induction, and most importantly next day alertness and functioning.

The new double blind placebo controlled trial with more than 790 insomnia patients aged 18-80, shows that 6 months continuous treatment with Circadin(R) is both safe and efficacious. The trial demonstrated improvements in sleep latency, quality of sleep and morning alertness particularly in elderly patients, with no withdrawal symptoms and rebound insomnia. "We are very excited about these preliminary Phase III results" said Professor Nava Zisapel, CSO of Neurim Pharmaceuticals, "because Circadin(R), previously shown to be a unique short term treatment for poor sleep quality, has now demonstrated long term efficacy and safety."

About Circadin(R)

Circadin(R) http://www.Circadin.info) is the first and only IP-protected prolonged-release melatonin to be approved as an ethical drug by health authorities. Administration of Circadin(R) to patients with primary insomnia improves sleep quality and morning alertness and facilitates sleep onset in patients aged 55 or over. Currently commercialized in Europe by H.Lundbeck A/S and Nycomed, and in Israel by Teva, Circadin(R) is undergoing registration in US, Asia-Pacific and Latin American markets.

About Neurim Pharmaceuticals

Neurim Pharmaceuticals (http://www.neurim.com) is headquartered in Israel with offices in Switzerland and the UK. The company was founded in 1991 and is focused on drug discovery and development of treatments for age-related disorders, primarily in the central nervous system (CNS).

    For More information:

    Eran Schenker, MD
    Medical Director & Corporate Business Development
    Neurim Pharmaceuticals Ltd.
    Tel: +972-3-7684914 Cell: +972-52-6689944
    EranS@Neurim.com



'/>"/>
SOURCE Neurim Pharmaceuticals LTD
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Jubilant to Work With Endo Pharmaceuticals on Drug Development
2. Access Pharmaceuticals Announces Granting of Two US Patents for MuGard(TM)
3. ADVENTRX Pharmaceuticals Announces Financing
4. Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex (Ferric Citrate) for the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients
5. Angiotech Pharmaceuticals announces FDA 510(k) clearance of the Option(TM) Inferior Vena Cava Filter
6. Celator(R) Pharmaceuticals Presents Data on the Activity of CPX-351 Against Leukemia at the European Hematology Association Congress
7. Poniard Pharmaceuticals to Present at the 8th Annual Needham Life Sciences Conference
8. Arena Pharmaceuticals to Present at the 8th Annual Needham Life Sciences Conference
9. Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598
10. VIA Pharmaceuticals DGAT1 Inhibitors Featured in American Diabetes Association Poster Presentation
11. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... 7, 2016 Neogen Corporation (NASDAQ: ... Dan Kephart as its chief science officer — ... his responsibilities at Neogen effective Jan. 1. ... the agribusiness unit of Thermo Fisher Scientific, as well ... Technologies. His extensive industry experience also includes the management ...
(Date:12/7/2016)... SAN DIEGO , Dec. 7, 2016  Biocom, the ... community, issued the statement below following passage of 21 st ... the House on November 30 by a 392-26 vote and ... This statement may be attributed to Joe Panetta , ... historic legislation that will give hope to millions of patients ...
(Date:12/7/2016)... 7, 2016  Muse bio, a privately-held company leading ... that Dr. Kevin Ness has been appointed ... Directors. Kevin succeeds Muse bio,s founding ... Chief Science Officer as well as remains Slade Professor, ... BioDesign Center at the RAS Energy Institute at the ...
(Date:12/7/2016)... , ... December 07, 2016 , ... ... pathology, announced today a new service to enable rapid migration of large pathology ... has remained one of the factors limiting adoption of digital pathology. Proscia’s free ...
Breaking Biology Technology:
(Date:11/29/2016)... 29, 2016 BioDirection, a privately held medical ... the objective detection of concussion and other traumatic brain ... completed a meeting with the U.S. Food and Drug ... Pre-Submission Package. During the meeting company representatives reviewed plans ... precursor to commencement of a planned pilot trial. ...
(Date:11/28/2016)... "The biometric system market projected to ... system market is in the growth stage and is ... biometric system market is expected to be valued at ... 16.79% between 2016 and 2022. Government initiative in adoption ... rising use of biometric technology in financial institutes and ...
(Date:11/22/2016)... --  MedNet Solutions , an innovative SaaS-based eClinical technology ... is pleased to announce that the company has been ... Awards as "Most Outstanding in eClinical Solutions" for ... recognition and growth for MedNet, which has effectively supported ... iMedNet ™ , MedNet,s flagship eClinical technology ...
Breaking Biology News(10 mins):